Available only in the US, the ExoDx Prostate Test (EPI) is a simple, non-invasive urine test that helps you and your doctor determine whether or not you need a prostate biopsy to determine your risk of prostate cancer.
Location: United States, Massachusetts, Waltham
Phone: +1 844-396-7663
Total raised: $154.6M
Investors 2
| Date | Name | Website |
| - | b2venture | b2venture.... |
| - | Forbion | forbion.co... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 31.07.2017 | Series C | $30M | - |
| 07.01.2016 | Series B | $60M | - |
| 11.03.2014 | Series B | $27M | - |
| 12.05.2010 | Series A | $20M | - |
Mentions in press and media 20
| Date | Title | Description |
| 13.12.2021 | Bio-Techne closes Exosome Diagnostics site at IZB | Bio-Techne had bought Exosome in 2018 for up to $575 million. Now the start-up, which offers non-invasive tests for detecting tumor diseases based on the company's proprietary platform for analyzing exosomes from body fluids, has to close. ... |
| 28.08.2017 | CareFirst BCBS, ExoDx band together on studies for diagnostic tests | The HealthWorx program allows CareFirst to join forces with early stage companies such as ExoDx. More specifically, the organizations are working together on evidence development studies for ExoDx diagnostic tests. Together, they will selec... |
| 24.07.2017 | Blue Ridge Capital Joins $30M Series C for Exosome Diagnostics | Waltham, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics Inc., a leader in the liquid biopsy market, today announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners.... |
| 24.07.2017 | Exosome Diagnostics Raises $30M Series C | Waltham, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics Inc., a leader in the liquid biopsy market, today announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners.... |
| 24.07.2017 | NGN Capital Joins $30M Series C for Exosome Diagnostics | Waltham, Mass., July 24, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics Inc., a leader in the liquid biopsy market, today announced the close of its $30 million Series C financing, led by insiders, Tiger Partners and Forbion Capital Partners.... |
| 21.03.2016 | Inside the race to diagnose cancer from a simple blood draw | BOSTON — It’s a medical puzzle that has snagged the attention — and the money — of Bill Gates, Jeff Bezos, and venture capitalists across the nation: Is it possible to diagnose cancer from a simple blood draw? Surgical biopsies are the norm... |
| 03.02.2016 | Q&A: Exosome Diagnostics launches first exosomal RNA-based liquid biopsy test | In a phone interview, Exosome Diagnostics’ CEO John Boyce shared more about the company’s progress and what’s next. How is what your doing unique and helpful when it comes to biopsies and successful diagnostics for certain cancer? There are... |
| 10.01.2016 | The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening? | But other companies have been touting advances in liquid biopsy screening for some time now. This is hardly the first gander at a pan-cancer test, right? San Diego-based Pathway Genomics, for instance, announced this past summer that it had... |
| 07.01.2016 | Exosome Diagnostics Closes $60M Series B Financing | Exosome Diagnostics, Inc., a Cambridge, MA-based developer of a liquid biopsy platform that enables non-invasive diagnosis of serious diseases, closed its $60m Series B financing. Backers included Forbion Capital Partners, NGN Capital, and ... |
| 02.09.2015 | Daily funding roundup - September 2, 2015 | Tanium landed $120M; NewsCred bagged $42M; Universal Avenue secured $5M ConnectedYard, an innovator in smart technology and the Internet of Things (IoT), today announced that it has closed a $2.2-million seed round of funding led by Playgro... |
Show more